^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    MIR138 (MicroRNA 138)

    i
    Other names: MIR138, MIR-138,MIR 138, MicroRNA 138
    Associations

    News

    Trials
    16d
    The ubiquitination-autophagy axis in cancer therapy resistance: mechanistic insights and therapeutic opportunities. (PubMed, Front Pharmacol)
    Finally, we discuss potential therapeutic strategies, including Proteolysis Targeting Chimeras (PROTACs), dual E3 ligase/autophagy inhibitors, and autophagy flux modulators, to overcome resistance and enhance treatment efficacy across multiple cancer types. These insights establish the foundation for targeting the ubiquitin-autophagy network as a cohesive strategy to combat refractory cancer.
    Review • Journal
    |
    ATG7 (Autophagy Related 7) • IL17RB (Interleukin 17 Receptor B) • MIR138 (MicroRNA 138) • SKP2 (S-phase kinase-associated protein 2) • USP1 (Ubiquitin Specific Peptidase 1) • USP14 (Ubiquitin Specific Peptidase 14)
    20d
    Unraveling the miRNA-EMT-stemness interplay in fusion-positive supratentorial ependymomas: Identifying therapeutic vulnerabilities. (PubMed, Biochem Biophys Res Commun)
    Supratentorial ependymomas with ZFTA-RELA fusions represent a highly aggressive pediatric brain tumor subtype, yet the post-transcriptional mechanisms driving their malignancy remain unclear. This study fills a critical gap by systematically profiling miRNA expression in fusion-positive and fusion-negative supratentorial ependymomas, revealing a distinct fusion-associated miRNA signature. The identification of hsa-miR-138-5p upregulation and hsa-miR-135b-5p/hsa-miR-216a-3p downregulation, converging on key oncogenic nodes such as TERT, YAP1, RELA, and TP53, provides novel mechanistic insight into how fusion-driven miRNA dysregulation enhances epithelial-mesenchymal transition and stemness. The findings suggest that miRNA-fusion interactions play an important role in tumor aggressiveness and highlight hsa-miR-138-5p as a potential biomarker for disease progression. Clinically, the work advances understanding of fusion-driven ependymoma biology and lays the foundation for developing miRNA-based diagnostic and therapeutic strategies targeting molecular mechanisms of tumor progression.
    Journal
    |
    TP53 (Tumor protein P53) • YAP1 (Yes associated protein 1) • FUS (FUS RNA Binding Protein) • CDH2 (Cadherin 2) • MIR135B (MicroRNA 135b) • MIR216A (MicroRNA 216a) • NES (Nestin) • SNAI2 (Snail Family Transcriptional Repressor 2) • MIR138 (MicroRNA 138) • RELA (RELA Proto-Oncogene) • ZFTA (Zinc Finger Translocation Associated)
    1m
    MicroRNA-138 regulation promotes the efficacy of oncolytic herpes virus G47Δ for malignant brain tumor therapy. (PubMed, Mol Ther Oncol)
    G47Δ combined with in vivo miR-138 inhibition significantly augmented efficacy compared with G47Δ alone. These findings identify miR-138 as both an antiviral regulator and immune modulator, and demonstrate that its inhibition potentiates G47Δ efficacy, providing rationale for a novel therapeutic strategy for malignant brain tumors.
    Journal
    |
    CD8 (cluster of differentiation 8) • STAT1 (Signal Transducer And Activator Of Transcription 1) • MIR138 (MicroRNA 138)
    1m
    MicroRNA-138-2-3p inhibits cell migration, invasion and EMT process in non-small-cell lung cancer by targeting antizyme inhibitor 1. (PubMed, Rev Invest Clin)
    The results suggest that miR-138-2-3p inhibits the malignant phenotype of NSCLC cells by targeting AZIN1.
    Journal
    |
    MIR138 (MicroRNA 138)
    1m
    Differentially Expressed Genes Associated with the Development of Cervical Cancer. (PubMed, Int J Mol Sci)
    The publicly available microarray datasets, including GSE39001, GSE9750, GSE7803, GSE6791, GSE63514, and GSE52903 in combination with bioinformatics database predictions, were used to identify differential expression genes, potential biomarkers, and therapeutic targets for cervical cancer; additionally, we undertook bioinformatic analysis to determine gene ontology and possible miRNA targets related to our DEGs...Interestingly, hub proteins KIF4A, NUSAP1, BUB1B, CEP55, DLGAP5, NCAPG, CDK1, MELK, KIF11, and KIF20A were found to be potentially regulated by several miRNAs, including miR-107, miR-124-3p, miR-147a, miR-16-5p, miR-34a-5p, miR-34c-5p, miR-126-3p, miR-10b-5p, miR-23b-3p, miR-200b-3p, miR-138-5p, miR-203a-3p, miR-214-3p, and let-7b-5p. The relationship between these genes highlights their potential as candidate biomarkers for further research in treatment, diagnosis, and prognosis.
    Journal
    |
    TP53 (Tumor protein P53) • TOP2A (DNA topoisomerase 2-alpha) • RAD51 (RAD51 Homolog A) • MIR200B (MicroRNA 200b) • MIR34A (MicroRNA 34a-5p) • RAD51AP1 (RAD51 Associated Protein 1) • NUSAP1 (Nucleolar and Spindle Associated Protein 1) • ELF3 (E74 Like ETS Transcription Factor 3) • FOXM1 (Forkhead Box M1) • MELK (Maternal Embryonic Leucine Zipper Kinase) • CDK1 (Cyclin-dependent kinase 1) • KIF11 (Kinesin Family Member 11) • MIR126 (MicroRNA 126) • MIR16 (MicroRNA 16) • MIR23b (MicroRNA 23b) • NCAPG (Non-SMC Condensin I Complex Subunit G) • PLOD2 (procollagen-lysine,2-oxoglutarate 5-dioxygenase 2) • BUB1B (BUB1 Mitotic Checkpoint Serine/Threonine Kinase B) • CEP55 (Centrosomal Protein 55) • CXCL14 (C-X-C Motif Chemokine Ligand 14) • E2F1 (E2F transcription factor 1) • KIF20A (Kinesin Family Member 20A) • KIF4A (Kinesin Family Member 4A) • MCM2 (Minichromosome maintenance complex component 2) • MCM5 (Minichromosome Maintenance Complex Component 5) • MIR10B (MicroRNA 10b) • MIR138 (MicroRNA 138) • MIR203A (MicroRNA 203a) • MIR214 (MicroRNA 214) • MIRLET7B (MicroRNA Let-7b) • RELA (RELA Proto-Oncogene) • RFC4 (Replication Factor C Subunit 4) • MIR124-3 (MicroRNA 124-3)
    2ms
    In-silico pharmacological insights into the therapeutic potential of microRNAs for microplastic-associated cancers. (PubMed, Front Cell Dev Biol)
    Priorities for validation include reporter assays, gene/protein modulation, phenotypic rescue, and in vivo testing in MP-exposed models. Collectively, our results nominate miRNAs as candidate tools to interrogate and potentially mitigate MP-associated carcinogenic mechanisms.
    Review • Journal
    |
    MIR331 (MicroRNA 331) • MIR370 (MicroRNA 370) • MIR490 (MicroRNA 490) • MIR638 (MicroRNA 638) • MIR760 (MicroRNA 760) • MIR138 (MicroRNA 138) • MIR483 (MicroRNA 483) • MIR520A (MicroRNA 520a) • MIR532 (MicroRNA 532)
    2ms
    Association between hypertensive patients of Kazakh nationality in Xinjiang and T lymphocytes microRNAs. (PubMed, Medicine (Baltimore))
    The area under the miRNAs curve for differential expression of lymphocytes in Kazakh hypertensive patients, where miR-423-5p, area under the curve (AUC): 0.696 (95% confidence interval (CI): 0.533-0.859); MiR-320a-3p, AUC: 0.764 (95% CI: 0.609-0.919). The expression of miR-92a-3p, miR-423-5p, and miR-320a-3p in T lymphocytes of Kazakh hypertensive patients is downregulated, with good diagnostic reference value (P < .05).
    Journal
    |
    IFNG (Interferon, gamma) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL17A (Interleukin 17A) • MIR320A (MicroRNA 320a) • MIR138 (MicroRNA 138) • MIR15B (MicroRNA 15b) • MIR423 (MicroRNA 423)
    4ms
    In silico analysis of a MicroRNA regulatory network Influencing mitochondrial fission in hepatocellular carcinoma. (PubMed, Mitochondrion)
    Molecular docking studies demonstrated favorable binding affinities of FDA-approved HCC drugs (sorafenib, lenvatinib, and regorafenib) to these binding pockets, suggesting an off-target mechanism by which these drugs might influence mitochondrial function through the hsa-miR-138-5p pathway. These findings contribute to the growing understanding of miRNA-mediated regulation in HCC and offer a foundation for developing novel microRNA-targeting drugs to modulate mitochondrial dynamics to manage HCC progression.
    Journal
    |
    WDR5 (WD Repeat Domain 5) • MIR138 (MicroRNA 138)
    |
    sorafenib • Lenvima (lenvatinib) • Stivarga (regorafenib)
    5ms
    Deep Learning-Based DNA Methylation Detection in Cervical Cancer Using the One-Hot Character Representation Technique. (PubMed, Diagnostics (Basel))
    These findings establish the potential of the proposed UNet-based approach as a reliable and scalable tool for early detection of epigenetic modifications. Thus, the work contributes significantly to improving biomarker discovery and diagnostics in cervical cancer research.
    Journal
    |
    MIR100 (MicroRNA 100) • MIR484 (MicroRNA 484) • MIR138 (MicroRNA 138)
    6ms
    Functional Role of miR-138-5p and miR-200b-3p in Testicular Germ Cell Tumors: Molecular Insights into Seminoma and Teratoma Pathogenesis. (PubMed, Int J Mol Sci)
    MiRNAs identified through bioinformatics analyses, and their predicted regulatory roles in key oncogenic pathways, represent potential therapeutic targets or regulators of biological processes. However, further experimental validation is needed to confirm these findings.
    Journal • IO biomarker
    |
    CTNNB1 (Catenin (cadherin-associated protein), beta 1) • MIR200B (MicroRNA 200b) • MIR138 (MicroRNA 138)
    7ms
    Molecular and Genetic Pathogenesis of Oral Cancer: A Basis for Customized Diagnosis and Treatment. (PubMed, Biology (Basel))
    The knowledge of this molecular pathogenesis has not yet been translated into clinical practice, apart from the use of cetuximab, an EGFR antibody...Liquid biopsies, either resorting to circulating tumor cells, extracellular vesicles or cell-free nucleic acids, have the potential to bypass this problem, and have potential prognostic and staging value. We critically review the current knowledge on the molecular, genetic and epigenetic alterations in oral cancer, as well as the applications and challenges of liquid biopsies in its diagnosis, follow-up, and prognostic stratification.
    Review • Journal
    |
    TP53 (Tumor protein P53) • PTEN (Phosphatase and tensin homolog) • HRAS (Harvey rat sarcoma viral oncogene homolog) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • CCND1 (Cyclin D1) • CDH1 (Cadherin 1) • FAT1 (FAT atypical cadherin 1) • ADAM9 (ADAM Metallopeptidase Domain 9) • MIR21 (MicroRNA 21) • MGAM (Maltase-Glucoamylase) • SOX17 (SRY-Box Transcription Factor 17) • MIR100 (MicroRNA 100) • MIR211 (MicroRNA 211) • MIR221 (MicroRNA 221) • MIR184 (MicroRNA 184) • MIR31 (MicroRNA 31) • MIR375 (MicroRNA 375) • CTTN (Cortactin) • MIR133B (MicroRNA 133b) • MIR138 (MicroRNA 138) • MIR200 (MicroRNA 200) • MIR203A (MicroRNA 203a) • MIR222 (MicroRNA 222)
    |
    Erbitux (cetuximab)
    10ms
    Simultaneous Targeting of Tumor Cells and Tumor-Associated Macrophages To Reprogram Glioblastoma Using Trypsinized Extracellular Vesicles Carrying Tumor Suppressive MicroRNA. (PubMed, Nano Lett)
    FA-labeled trypsinized EVs (tEVs) loaded with miR-138 inhibit tumor growth, depolarize TAMs, and enhance antitumor immunity. This study represents the first preclinical attempt to modulate tumor cells and innate immunity via miRNA-loaded tEVs, offering a novel and more effective therapeutic approach to GBM treatment.
    Journal
    |
    MIR138 (MicroRNA 138)